Abstracts

Filters

Clear Filters
All Days Sun, Sep 28 Mon, Sep 29 Tue, Sep 30 Wed, Oct 01

Tuesday, September 30

2:30 PM - 2:40 PM PT

329 - Phase II Trial of 'Re-Priming' Radiation Therapy for Relapsed/Refractory Non-Hodgkin Lymphoma Patients in Incomplete Response after Chimeric Antigen Receptor T-cell (CAR-T) Therapy
Speaker: Kumar, Kiran, MD, MBA - UT Southwestern Medical Center, Dallas, TX
2:30 PM - 2:40 PM PT

334 - Validation of a Poissonian LQ-Based Population TCP Model for Breast Cancer Radiotherapy
Speaker: Unterkirhers, Sergejs, DSc, PhD, MS, BS - Radiotherapy Hirslanden, Zurich, Zurich
2:30 PM - 3:45 PM PT

Hem 2: New Protocols, New Paradigms: Clinical Trials Shaping the Future of Hematologic RT
Speaker: Mohindra, Pranshu, MD, MMM - University Hospitals Seidman Cancer Center, Cleveland, OH, Cleveland, OH
2:30 PM - 2:40 PM PT

LBA 08 - Comprehensive Patient Reported Outcomes (PROs) from NRG LU005: A Randomized Trial Of Chemoradiation (CRT) +/- Atezolizumab In Limited-Stage Small Cell Lung Cancer (LS-SCLC)
Speaker: Movsas, Benjamin, MD, FASTRO - Henry Ford Cancer Institute, Detroit, Michigan
2:30 PM - 3:45 PM PT

Radiation and Cancer Physics 7: AI-Driven Imaging and Predictive Modeling
Speaker: Sheng, Ke, PhD - University of California, San Francisco, San Francisco, CA
2:40 PM - 2:50 PM PT

330 - Pembrolizumab and Involved Site Radiation Therapy Alone as an Alternative to Transplant in Patients with Localized Failure following Chemotherapy for Hodgkin Lymphoma: A Prospective Multicenter Phase II Study
Speaker: Dreyfuss, Alexandra, MD, MS - University of Miami - Sylvester Cancer Center, Coral Gables, FL
2:40 PM - 2:50 PM PT

335 - Predicting Voxel-Level Local Progression for Locally Advanced NSCLC following Chemoradiation Using Multi-Task Deep Learning
Speaker: Fu, Jie, PhD - University of Washington, Seattle, WA
2:40 PM - 2:50 PM PT

LBA 10 - Two-year toxicity outcomes from PACE-C: Stereotactic Body Radiotherapy (SBRT) versus moderate hypofractionated radiotherapy (MHRT)
Speaker: Ratnakumaran, Ragu, MBBS - Royal Marsden NHS Foundation Trust, Sutton, London
2:50 PM - 3:00 PM PT

331 - Prospective Study of Split-Course Bridging Radiotherapy (SC-BRT) Prior to CAR T-Cells for Relapsed/Refractory B-Cell Lymphomas
Speaker: Imber, Brandon, MD, MS - Memorial Sloan Kettering Cancer Center, New York, NY
2:50 PM - 3:00 PM PT

336 - An Explainable Deep Model for Risk Scoring and Accurate Radionecrosis Identification Following Brain Metastasis Stereotactic Radiosurgery
Speaker: Zhao, Jingtong, MS, BS - Duke University, Durham, NC
2:50 PM - 3:00 PM PT

LBA 11 - Addition of Metastasis-Directed Therapy to Standard of Care: Primary Aggregate Analysis and Immunologic Correlatives of the Phase II Randomized EXTEND Trial
Speaker: Sherry, Alexander, MD - Mayo Clinic Rochester, Rochester, MN
3:00 PM - 3:10 PM PT

332 - Differential Impact of Total Body Irradiation- vs. Chemotherapy-Based Myeloablative Conditioning on Oral Microbiota and Mucositis after Allogeneic Transplantation
Speaker: Ebadi, Maryam, MD - University of Washington, Seattle, WA